A Randomized Phase III Multicenter Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-chemotherapy (R-CHT) for Relapsed/Refractory FL Patients Not Eligible for Autologous Transplantation (ASCT).
Phase of Trial: Phase III
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms FIL_RENOIR12
- 31 Oct 2019 Planned End Date changed from 1 Mar 2022 to 1 Dec 2025.
- 31 Oct 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Dec 2022.
- 31 Aug 2018 Biomarkers information updated